Hepatic artery infusion + immunotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests combining a liver-directed chemotherapy infusion (HAIC) with immunotherapy to shrink advanced bile duct cancer that cannot be removed surgically. The goal is to slow tumor growth and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced bile duct cancer that cannot be removed by surgery and has not been treated with systemic therapy before.
- You have at least one tumor that can be measured on scans.
- You are in good general health (able to do most daily activities).
- Your liver function is adequate (Child-Pugh class A or B).
- Your expected survival is at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of drugs to treat advanced bile duct cancer that cannot be removed by surgery. The treatment may help shrink tumors and improve outcomes.
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.